Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Baclofen

Preparation Calculator

USE IF: Spasticity due to neurologic conditions (spinal cord injury, multiple sclerosis, stroke).

AVOID IF: Severe renal impairment without dose adjustment, high sedation risk without monitoring, or prior baclofen hypersensitivity.

Baclofen

Antispastic agent (GABA-B receptor agonist)

AdultPediatricNeurologyRehabWardHigh-yield

Indication

Spasticity • Neurologic muscle hypertonicity

At a glance

INDICATIONS (CORE USE)

- Spasticity (MS, spinal cord injury, stroke-related)

ADULT DOSE (STANDARD)

Start low (e.g., 5 mg TID) Titrate gradually based on response and tolerance

MAX DOSE

Typically up to about 80 mg/day (divided doses)

Route

PO (oral) • Intrathecal (specialist/pump only)

PEDIATRIC DOSE

Specialist/protocol-based

Do not miss

Must-not-miss safety points

Major warning

- Abrupt discontinuation -> withdrawal (agitation, hallucinations, seizures) - Intrathecal baclofen withdrawal -> LIFE-THREATENING (delirium, hyperthermia, seizures) - Renal impairment -> accumulation -> coma / severe CNS depression (dose reduce or avoid) - Sedation and respiratory depression (especially with CNS depressants)

Indications

Primary

  • Spasticity from neurologic conditions

Secondary

  • Intrathecal baclofen for severe refractory spasticity (specialist management)

Dosing

STANDARD (ADULT PO)

Start 5 mg TID and titrate slowly; adjust based on response and sedation.

ADULT DOSE

Use oral divided dosing and increase in small increments based on functional response and adverse effects. Avoid rapid escalation; reassess sedation and mental status after each adjustment.

PEDIATRIC DOSE

Specialist/protocol-based dosing only.

MAX DOSE

Typically up to about 80 mg/day in divided doses (individualize to tolerability and safety).

Practical Note

- Slow titration reduces adverse effects - Do not escalate rapidly - Dose reduction required in renal impairment - Intrathecal therapy is specialist-managed only (pump systems)

Warnings

Clinical warnings

  • Sedation/CNS depression
  • Respiratory depression (higher doses or interaction burden)
  • Hypotonia and weakness
  • Withdrawal syndrome if stopped abruptly
  • Adverse effects: - Drowsiness - Dizziness - Confusion - Weakness

Contraindications

  • Known hypersensitivity
  • Severe renal impairment (use caution or avoid depending on formulation/context)

Drug interactions

  • CNS depressants (opioids, benzodiazepines, alcohol) -> increased risk of respiratory depression
  • Other sedating agents -> additive CNS depression

Special populations

Pediatrics

Specialist/protocol-based

Pregnancy

Use risk-benefit assessment with specialist input; monitor for CNS effects and functional impact.

Lactation

See lactation references and product labeling.

Renal impairment

Dose reduction is required; renal dysfunction markedly increases accumulation and CNS toxicity risk.

Hepatic impairment

Hepatic function is usually less critical than renal function for routine dosing decisions.

Elderly

Higher sensitivity to sedation, confusion, and falls; titrate more cautiously.

Administration

- Oral divided dosing - Intrathecal baclofen is specialist-only (pump systems) - Do not stop abruptly; taper when discontinuing

Monitoring

  • Monitor: - Spasticity response - Level of sedation - Mental status - Renal function
  • Recheck: - After dose changes - Periodically during chronic use
  • Hold if:
    - Excess sedation or reduced consciousness
    - Confusion/delirium
    - Respiratory depression

Overdose / toxicity

Clinical Picture

CNS depression to coma, respiratory depression, and hypotonia.

Immediate Actions

- Airway protection (priority) - Ventilatory support if needed - ICU monitoring if severe CNS depression

Antidote

None specific -> supportive care

Decontamination

Consider only in selected early presentations with airway protection and toxicology guidance.

Escalation

Escalate for higher-acuity monitoring when respiratory or neurologic compromise is present.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

  • Baclofen toxicity can mimic encephalopathy or stroke -> check renal function
  • Always taper -> never stop abruptly
  • Renal function is the key safety determinant

Clinical

  • Intrathecal baclofen withdrawal can be severe and life-threatening

Safety

  • Most common serious error is accumulation in renal impairment

Pharmacy Tool

Preparation Calculator

Baclofen 10 mg/mL oral suspension

suspension · oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

- Renal clearance is dominant - Accumulates in renal dysfunction

Mechanism of action

- GABA-B receptor agonist -> reduces spinal reflex activity

Common brand names

Saudi Arabia

Lioresal, Baclofen

Global

Lioresal (example), Baclofen (generic)

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Institutional spasticity and baclofen titration/withdrawal pathways
  • Product labeling for oral and intrathecal baclofen
  • Local renal dosing and medication safety guidance